Skip to main content

MedRhythms Announces Positive Topline Results from Pivotal Trial in Chronic Stroke

PORTLAND, Maine, Jan. 17, 2023. MedRhythms announced today that the company's pivotal trial for MR-001, a novel digital intervention in development to treat gait deficits in chronic stroke, was successfully completed and met its primary endpoint.

"There are at least three and a half million chronic stroke survivors living with gait deficits for which there is currently no standard of care in the U.S.," said Brian Harris, CEO and Co-Founder of MedRhythms. "The topline results from our pivotal trial in chronic stroke suggest that our product can help address this unmet need to improve walking. Successfully completing our pivotal trial with MR-001 is a critical milestone and represents significant progress towards getting this solution into the hands of patients who need it."

The multi-site randomized controlled trial was conducted at eight of the top rehabilitation hospitals and research institutions in the U.S., including Shirley Ryan AbilityLab, Spaulding Rehabilitation Hospital, the Boston University Neuromotor Recovery Laboratory, Kessler Foundation, Mount Sinai Health System, Atrium Health, and The University of North Carolina at Chapel Hill. The trial included adult chronic stroke survivors who participated in thirty-minute sessions three times per week over a five-week intervention period. The study participants either used MR-001 or were part of an active control group. MedRhythms intends to submit this important clinical data for peer review in a scientific journal and to present the data at a major conference later this year.

MedRhythms has a robust pipeline of next-generation neurotherapeutics in active development. The company aims to bring these solutions to a wide range of patients with neurologic injury and disease. MR-001, in development to treat chronic stroke gait deficits, is anticipated to be the first product the company brings to market. Other advanced pipeline programs include MR-004, a novel, investigational prescription digital therapeutic targeting gait deficits in multiple sclerosis for which the company entered into a license agreement with Biogen. Furthermore, the company has initiated feasibility studies of MR-005, in development to treat gait deficits in Parkinson's disease, and MR-010, in development to treat gait deficits in post-acute stroke.

About MedRhythms
MedRhythms is pioneering the development of next-generation neurotherapeutics designed to improve walking, mobility and related functional outcomes via a proprietary, patented technology platform. The company's platform combines sensors, software, and music with advanced neuroscience to target neural circuitry. The company is developing a pipeline of digital therapeutics across a range of neurological conditions, including stroke, multiple sclerosis and Parkinson's disease. The company's pipeline product for chronic stroke walking deficits received Breakthrough Device designation in 2020 and the company raised a Series B financing round in 2021 led by Morningside Ventures and Advantage Capital. MedRhythms is headquartered in Portland, Maine. For more information, visit www.medrhythms.com.

Forward-Looking Statements
THIS MANAGEMENT COMMENTARY CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO THE COMPANY THAT ARE BASED ON INFORMATION AVAILABLE TO US AS OF THE DATE HEREOF. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS ABOUT THE COMPANY'S BELIEFS, DESIGNS, ANTICIPATION, AIMS, GOALS, EXPECTATIONS AND POTENTIAL RESULTS ARE FORWARD-LOOKING STATEMENTS. IN ADDITION, THE WORDS "WILL," "MAY," "BELIEVE," "ANTICIPATE," "INTEND," "ESTIMATE," "EXPECT," "PROJECT," "PLAN," "SHOULD," "COULD," AND SIMILAR EXPRESSIONS, AND THEIR VARIATIONS AND NEGATIVES, AS THEY RELATE TO THE COMPANY OR THE FUTURE PERFORMANCE OF THE COMPANY, ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. SUCH FORWARD LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES, ASSUMPTIONS AND OTHER IMPORTANT FACTORS THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARD LOOKING STATEMENTS. THIS MANAGEMENT COMMENTARY SPEAKS ONLY AS OF THE DATE HEREOF AND THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO UPDATE THIS COMMENTARY IN THE FUTURE.

SOURCE MedRhythms

Posted: January 2023

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.